Desire for reversal after tubal sterilization in the United States, 2006-2023

2006-2023年美国输卵管结扎术后复通手术需求

阅读:1

Abstract

OBJECTIVE: To describe trends in the prevalence of tubal sterilization and subsequent desire for reversal among US women and identify sociodemographic factors associated with desires for reversal. DESIGN: Nationally representative data were collected from US women between 2006 and 2023 in a series of six cross-sectional waves of the National Survey of Family Growth. We employed weighted logistic regression models to assess associations between sociodemographic variables and outcomes of interest. SUBJECTS: Nationally representative samples of US women aged 15-49 surveyed between 2006 and 2023. EXPOSURE: Sociodemographic variables including age at interview, race and ethnicity, health insurance status, poverty level, education, marital status, parity, and timing of sterilization. MAIN OUTCOME MEASURES: Tubal sterilization, desire for tubal reversal surgery, and experience with tubal reversal surgery. RESULTS: In 2022-2023, 21.3% of US individuals who had undergone tubal sterilization reported a desire for reversal. Only 0.1% of those who desired reversal had undergone reversal surgery. Rates of tubal sterilization and desired reversal were higher in prior years; in 2006, a desire for reversal surgery was reported by 26.8% of respondents. Desire for reversal was more likely among nulliparous individuals, those younger than 30 years, those living below the federal poverty level, and among Hispanic and Black women compared with White, non-Hispanic women. CONCLUSION: One of every five US individuals who undergo tubal sterilization subsequently reports a desire for reversal. As <1% of those who desire reversal obtain reversal surgery, efforts to support informed decision-making before permanent contraceptive surgery remain important.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。